Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label phase III study. The treatment was compare the efficacy and
safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX)
treating stage Ⅲ gastric cancer as adjuvant setting